HN2008001934A - 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen. - Google Patents

18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen.

Info

Publication number
HN2008001934A
HN2008001934A HN2008001934A HN2008001934A HN2008001934A HN 2008001934 A HN2008001934 A HN 2008001934A HN 2008001934 A HN2008001934 A HN 2008001934A HN 2008001934 A HN2008001934 A HN 2008001934A HN 2008001934 A HN2008001934 A HN 2008001934A
Authority
HN
Honduras
Prior art keywords
methyl
group
androst
well
espirox
Prior art date
Application number
HN2008001934A
Other languages
English (en)
Inventor
Bohlmann Rolf
Kuhnke Joachim
Hubner Jan
Gallus Norbert
Menges Frederik
Borden Steffen
Muhn Hans-Peter
Prelle Katja
Original Assignee
Bayer Schering Pharma Ag Epix Pharmaceutica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2008001934(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag Epix Pharmaceutica filed Critical Bayer Schering Pharma Ag Epix Pharmaceutica
Publication of HN2008001934A publication Critical patent/HN2008001934A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Abstract

ESTA INVENCION DESCRIBE LOS NUEVOS 18-METIL-19-NOR-ANDROST-4-EN 17-17 ESPIROESTERES DE LA FORMULA GENERAL I FORMULA I DONDE Z ES UN ATOMO DE OXIGENO, DOS ATOMOD DE HIDROGENO, UN GRUPO = NOR O = NNHSO2R7, EN DONDE R ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO DE CADENA LINEAL ORAMIFICADA CON 1 A 4 O BIEN, 3 A 4 ATOMOS DE CARBONO R4 ES UN ATOMO DE HIDROGENO, UN ATOMO DE HALOGENO O UN GRUPO DE TRIFLUOROMETILO Y R6 Y/O R7 PUEDEN ESTAR EN POSICION a O B Y R6 Y R7 SON, DE MODO INDEPENDIENTE ENTRE SI, DE CADENA LINEAL O RAMIFICADA CON 2 A 4 O, BIEN 3 O 4 ATOMOS DE CARBONO O UN GRUPO CICLOALQUILO SATURADO CON 3 A 5 ATOOS DE CARBONO O SON JUNTOS UN GRUPO METILENO O UN ENLACE. LOS NUEVOS COMPUESTOS POSEEN GESTAGENICA Y ANTIMINERALCORTICOIDE.
HN2008001934A 2006-06-29 2008-12-29 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen. HN2008001934A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
HN2008001934A true HN2008001934A (es) 2012-01-17

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001934A HN2008001934A (es) 2006-06-29 2008-12-29 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen.

Country Status (41)

Country Link
US (1) US7846917B2 (es)
EP (1) EP2038294B1 (es)
JP (1) JP5326085B2 (es)
KR (1) KR101440640B1 (es)
CN (1) CN101511857B (es)
AR (1) AR061736A1 (es)
AT (1) ATE490967T1 (es)
AU (1) AU2007263944B2 (es)
BR (1) BRPI0713934A2 (es)
CA (1) CA2656443C (es)
CL (1) CL2007001919A1 (es)
CO (1) CO6150134A2 (es)
CR (1) CR10548A (es)
CY (1) CY1111658T1 (es)
DE (2) DE102006030416A1 (es)
DK (1) DK2038294T3 (es)
DO (1) DOP2008000089A (es)
EC (1) ECSP089014A (es)
ES (1) ES2357698T3 (es)
GT (1) GT200800307A (es)
HK (1) HK1133659A1 (es)
HN (1) HN2008001934A (es)
HR (1) HRP20110161T1 (es)
IL (1) IL195935A0 (es)
MA (1) MA30596B1 (es)
MX (1) MX2009000082A (es)
MY (1) MY155015A (es)
NO (1) NO20090459L (es)
NZ (1) NZ573951A (es)
PE (1) PE20080995A1 (es)
PL (1) PL2038294T3 (es)
PT (1) PT2038294E (es)
RS (1) RS51722B (es)
RU (1) RU2440365C2 (es)
SI (1) SI2038294T1 (es)
TN (1) TNSN08518A1 (es)
TW (1) TWI413645B (es)
UA (1) UA94952C2 (es)
UY (1) UY30451A1 (es)
WO (1) WO2008000521A1 (es)
ZA (1) ZA200900673B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
WO2013160200A1 (de) * 2012-04-23 2013-10-31 Bayer Pharma Aktiengesellschaft ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
US20160262923A1 (en) * 2013-10-18 2016-09-15 Bayer Oy Intrauterine delivery system
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) * 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1148061B1 (en) 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

Also Published As

Publication number Publication date
UY30451A1 (es) 2008-01-31
ATE490967T1 (de) 2010-12-15
DOP2008000089A (es) 2009-02-15
RU2440365C2 (ru) 2012-01-20
DE502007005902D1 (de) 2011-01-20
PL2038294T3 (pl) 2011-05-31
ECSP089014A (es) 2009-01-30
TNSN08518A1 (en) 2010-04-14
BRPI0713934A2 (pt) 2012-12-04
UA94952C2 (uk) 2011-06-25
JP5326085B2 (ja) 2013-10-30
HK1133659A1 (es) 2010-04-01
TW200811193A (en) 2008-03-01
DE102006030416A1 (de) 2008-01-03
CA2656443A1 (en) 2008-01-03
PT2038294E (pt) 2011-03-14
RS51722B (en) 2011-10-31
CN101511857A (zh) 2009-08-19
WO2008000521A1 (de) 2008-01-03
CN101511857B (zh) 2012-10-31
IL195935A0 (en) 2009-09-01
CY1111658T1 (el) 2015-10-07
US20080153787A1 (en) 2008-06-26
NZ573951A (en) 2011-06-30
KR20090021294A (ko) 2009-03-02
JP2009541405A (ja) 2009-11-26
CO6150134A2 (es) 2010-04-20
EP2038294B1 (de) 2010-12-08
HRP20110161T1 (hr) 2011-04-30
AR061736A1 (es) 2008-09-17
GT200800307A (es) 2009-11-03
US7846917B2 (en) 2010-12-07
TWI413645B (zh) 2013-11-01
CL2007001919A1 (es) 2008-05-16
CR10548A (es) 2009-01-27
MA30596B1 (fr) 2009-07-01
ZA200900673B (en) 2010-04-28
ES2357698T3 (es) 2011-04-28
AU2007263944A1 (en) 2008-01-03
MY155015A (en) 2015-08-28
CA2656443C (en) 2014-10-07
EP2038294A1 (de) 2009-03-25
NO20090459L (no) 2009-03-10
KR101440640B1 (ko) 2014-09-22
AU2007263944B2 (en) 2013-07-18
PE20080995A1 (es) 2008-10-03
DK2038294T3 (da) 2011-03-28
SI2038294T1 (sl) 2011-04-29
MX2009000082A (es) 2009-01-23
RU2009102772A (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
HN2008001934A (es) 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen.
ECSP034874A (es) Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
CR9930A (es) Compuestos
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
CR8402A (es) Indazol-o-glucosidos sustitutos
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
UY27542A1 (es) Derivados benzotiazol de nicotina o isonicotina
ECSP045255A (es) Cumarinas utiles como biomarcadores
EA200802213A1 (ru) Способы лечения заболеваний крови
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR8387A (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
BRPI0519521A2 (pt) derivados de tieno-piridina como aumentadores alostÉricos gaba-b
UY28679A1 (es) Nuevos derivados organofosforados de los indazoles y utilización como médicamentos.
ATE486079T1 (de) Azatricyclische verbindungen und deren verwendung
PA8658401A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
BRPI0512310A (pt) compostos quìmicos
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
BR0115996A (pt) Sulfamidotienopirimidinas
TW200609226A (en) New isobenzoxazinones and their use as ultraviolet light absorbers
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
EA200801139A1 (ru) Композиция для аэрозольной ингаляции